On April 28, 2026, Vietnam’s Ministry of Industry and Trade (MOIT) updated its Guidelines for Import Management of Medical Devices, introducing a streamlined registration pathway for infant monitors (classified under Nursery Furniture & Monitors). The change eliminates mandatory local type testing but requires submission of a valid Chinese NMPA Class II medical device filing certificate and a notarized English translation of the Chinese product instructions. This update is particularly relevant to medical device exporters, regulatory affairs professionals, and cross-border trade service providers operating between China and Vietnam.

Event Overview

On April 28, 2026, the Vietnamese Ministry of Industry and Trade (MOIT) issued an update to its Guidelines for Import Management of Medical Devices. For infant monitors (Nursery Furniture & Monitors category), MOIT removed the requirement for local type testing during registration. However, applicants must now submit: (1) a valid Class II medical device filing certificate issued by China’s National Medical Products Administration (NMPA); and (2) a notarized English translation of the Chinese-language product instructions. The revised process reduces the official registration timeline to 12 working days.

Industries Affected

Direct Exporters (China-based Manufacturers)

Chinese manufacturers already holding NMPA Class II filing for infant monitors are directly impacted—this change lowers technical entry barriers into Vietnam. The impact manifests in reduced time-to-market and lower pre-market validation costs, provided the NMPA filing remains active and covers the exact model submitted to MOIT.

Regulatory Affairs & Compliance Service Providers

Firms supporting medical device registration in Vietnam must adapt documentation workflows to incorporate NMPA filing verification and certified translation handling. The shift increases demand for bilingual (Chinese–English) notarial services and cross-jurisdictional regulatory alignment checks—not just for Vietnam, but as a potential precedent for other ASEAN markets.

Distributors & Importers (Vietnam-based)

Vietnamese importers of infant monitors must now verify upstream NMPA compliance before initiating registration. The absence of local type testing does not eliminate responsibility for product conformity; instead, due diligence shifts upstream to validating the authenticity and scope of the NMPA filing—and ensuring the submitted English instructions match the NMPA-registered version.

Key Considerations and Recommended Actions

Verify NMPA Filing Validity and Scope

Confirm that the existing NMPA Class II filing covers the exact product model, intended use, and technical specifications being registered in Vietnam. MOIT does not accept filings for similar or derivative models unless explicitly included in the original NMPA record.

Prioritize Certified Translation and Notarization

Engage qualified translation services with medical device regulatory experience to prepare the English instruction manual. Ensure the notarization explicitly references the Chinese source text and confirms it is a true and complete translation—MOIT may reject submissions with incomplete or non-notarized documents.

Monitor MOIT Implementation Guidance

While the policy update is effective as of April 28, 2026, MOIT has not yet published detailed procedural guidance (e.g., document templates, filing portals, or acceptance criteria for notarization). Stakeholders should track MOIT’s official announcements and consult licensed Vietnamese regulatory agents for early application feedback.

Editorial Observation / Industry Perspective

Observably, this revision reflects Vietnam’s broader trend of aligning certain regulatory requirements with established regional benchmarks—in this case, leveraging China’s NMPA Class II filing as a proxy for basic safety and performance assurance. Analysis shows the move is less about full mutual recognition and more about pragmatic risk-based harmonization: MOIT retains full authority over market surveillance and post-market enforcement, while shifting pre-market verification burden to a trusted third-party system. From an industry perspective, this is best understood as a procedural signal—not yet a systemic policy shift—indicating growing receptivity to foreign regulatory evidence where domestic capacity or timelines constrain efficiency. Continued monitoring is warranted, especially for whether similar provisions extend to other low-to-moderate-risk devices.

In summary, Vietnam’s updated infant monitor registration pathway offers a concrete efficiency gain for Chinese manufacturers with valid NMPA Class II filings—but only if documentation rigor and jurisdictional alignment are maintained. It does not reduce regulatory accountability; rather, it reconfigures where and how compliance is verified. Currently, this measure is better interpreted as a targeted operational adjustment than a broad regulatory liberalization.

Source: Vietnam Ministry of Industry and Trade (MOIT), Guidelines for Import Management of Medical Devices, updated April 28, 2026. Note: MOIT’s implementation details—including acceptable formats for notarization and digital submission procedures—remain pending official clarification and are subject to ongoing observation.